Lotiglipron

Last updated
Lotiglipron
Lotiglipron.svg
Identifiers
  • 2-{[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl}-3-{[(2S)-oxetan-2-yl]methyl}benzimidazole-5-carboxylic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C31H31ClN4O5
Molar mass 575.06 g·mol−1
3D model (JSmol)
  • C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1
  • InChI=1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1
  • Key:SVPYZAJTWFQTSM-UGDMGKLASA-N

Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist which was under development by Pfizer as a weight loss drug. [1] However, it was withdrawn from development in June 2023, after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity. [2]

See also

References

  1. ↑ US 10676465,Aspnes GE, et al.,"GLP-1 receptor agonists and uses thereof",issued 9 June 2020, assigned to Pfizer Inc
  2. ↑ Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.